This initiation adds a conservative bullish voice to a crowded consensus, but the combination of below-average firm accuracy, persistent insider selling, and downward EPS revisions creates a mixed setup. The elevated short interest (57.7%) is the most notable feature, a potential squeeze catalyst if the company delivers positive news, but not a reason to act on this analyst call alone.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 21 $25.07entry
- T+1 · 8w ago +2.71%α +2.73% · $25.75
- T+5 · 7w ago −13.52%α −13.24% · $21.68
- T+20 · 29d ago −33.11%α −31.78% · $16.77
- T+40 · todayOpen
- T+60 · in 28d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alliance Global Partners initiated coverage on Immunome Inc. (IMNM) with a Buy rating and a $32 price target, implying 33% upside from the current $23.97 close. The firm joins a heavily bullish consensus: 19 of 20 analysts rate IMNM Buy or Strong Buy, with only one Hold and no Sell ratings. The mean price target across 13 analysts is $36.31, with a high of $40 and a low of $30. Alliance Global's $32 target sits below the consensus mean and median, reflecting a more conservative stance relative to the Street. The firm's track record is below average, 41% accuracy on 92 calls with a -6.1% average return, which tempers the signal's weight. Over the past 30 days, analyst activity has been one upgrade and zero downgrades, though EPS revisions have been net negative: 7 downward revisions vs. 1 upward for the +1y period, and 10 downward vs. 0 upward for the current fiscal year. Insider selling has been notable, with CFO Isaac Barchas executing five sales totaling ~$2.9M in August and September 2026, including a $1.6M sale on August 11. Institutional activity is mixed: Citadel and Dimensional Fund Advisors more than doubled their positions, while JPMorgan and T. Rowe Price trimmed. Short interest stands at 57.7% of float, indicating elevated bearish positioning. The next earnings date is November 16, 2026, about 8 weeks out, so no near-term catalyst timing is in play. Bottom line: a new Buy initiation from a below-average-accuracy firm adds modest bullish coverage but is not a game-changer given the already crowded bullish consensus and persistent insider selling.
Impact Score
Consensus & Targets
The consensus is overwhelmingly bullish: 5 Strong Buy, 14 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 20 analysts. That's 95% Buy/Strong Buy, with only a single Hold. The direction is firmly positive, with no bearish voices.
Current price: $23.97. Mean target: $36.31, median: $36.00. High: $40 (HC Wainwright), Low: $30. Implied upside to mean: +51.5%. Alliance Global's $32 PT sits below the mean and median, making it the second-lowest target on the Street, a relatively conservative entry point within a bullish framework.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-09-21 | Alliance Global Partners | initiate | Buy | $32.00 |
| 2026-09-10 | HC Wainwright & Co. | reiterate | Buy | $40.00 |
| 2026-08-12 | Truist Securities | maintain | Buy | $38.00 |
| 2026-08-12 | Wedbush | maintain | Outperform | $35.00 |
| 2026-07-21 | Wedbush | reiterate | Outperform | $31.00 |
| 2026-06-12 | Wedbush | reiterate | Outperform | $31.00 |
| 2026-05-28 | Truist Securities | maintain | Buy | $37.00 |
| 2026-05-28 | Barclays | initiate | Overweight | $36.00 |
| 2026-05-15 | Leerink Partners | maintain | Outperform | $33.00 |
| 2026-05-13 | HC Wainwright & Co. | reiterate | Buy | $40.00 |
Over the past 30 days, there has been 1 upgrade (this initiation) and 0 downgrades. However, EPS revision trends are negative: for the current fiscal year, 10 downward revisions vs. 0 upward in the last 30 days; for the +1y period, 7 down vs. 1 up. Estimates are being revised lower, which creates a headwind for the bullish narrative.
Firm Track Record: Alliance Global Partners
Alliance Global Partners accuracy: 41% on 92 calls | avg return: -6.1%
Industry benchmark: mean 51% ± 10%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| JP Morgan | 100% | 2/2 | 32.2% | top tier |
| Stephens & Co. | 67% | 2/3 | 3.3% | top tier |
| Evercore ISI Group | 50% | 1/2 | 33.3% | below average |
| Lake Street | 50% | 1/2 | 7.7% | below average |
| Guggenheim | 50% | 2/4 | 11.8% | below average |
| Piper Sandler | 33% | 1/3 | -6.5% | below average |
| Wedbush | 25% | 1/4 | -19% | below average |
Alliance Global Partners has a 41% accuracy rate on 92 scored calls with an average return of -6.1%, placing it below average among firms covering IMNM. For context, the best-performing firm on this ticker is JP Morgan (100% on 2 calls, +32.2% avg return), followed by Stephens & Co. (67% on 3 calls, +3.3%). The worst is Wedbush (25% on 4 calls, -19% avg return). Alliance Global's initiation carries less conviction than a call from a top-tier firm.
Earnings Estimates
Next earnings: Nov 16, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1y | $-2.48 | $-2.90 to $-2.11 | $55.6M | ↑1 ↓0 |
| 0y | $-2.31 | $-2.56 to $-2.02 | $333.3K | ↑0 ↓0 |
| 0q | $-0.59 | $-0.71 to $-0.41 | $166.7K | ↑3 ↓0 |
| +1q | $-0.61 | $-0.75 to $-0.38 | $166.7K | ↑2 ↓0 |
Cross-Platform Signals
Insider selling is a notable contra-signal: CFO Isaac Barchas sold ~$2.9M in August-September 2026, including a $1.6M sale on August 11. Director Higgins Jack sold $334K on September 11. No insider buys are present. Institutional activity is mixed, Citadel (+179%) and Dimensional (+1001%) added aggressively, while JPMorgan (-33.5%) and T. Rowe Price (-38%) trimmed. Short interest is elevated at 57.7% of float, indicating heavy bearish positioning that could fuel a squeeze if positive catalysts emerge. The insider selling diverges from the bullish analyst signal, reducing conviction.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Viewing Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers